JP2016503067A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503067A5
JP2016503067A5 JP2015549834A JP2015549834A JP2016503067A5 JP 2016503067 A5 JP2016503067 A5 JP 2016503067A5 JP 2015549834 A JP2015549834 A JP 2015549834A JP 2015549834 A JP2015549834 A JP 2015549834A JP 2016503067 A5 JP2016503067 A5 JP 2016503067A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cdr
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015549834A
Other languages
English (en)
Japanese (ja)
Other versions
JP6449777B2 (ja
JP2016503067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/077264 external-priority patent/WO2014100740A1/en
Publication of JP2016503067A publication Critical patent/JP2016503067A/ja
Publication of JP2016503067A5 publication Critical patent/JP2016503067A5/ja
Application granted granted Critical
Publication of JP6449777B2 publication Critical patent/JP6449777B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015549834A 2012-12-21 2013-12-20 抗ntb−a抗体ならびに関連する組成物および方法 Expired - Fee Related JP6449777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
US61/745,239 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018203019A Division JP6817674B2 (ja) 2012-12-21 2018-10-29 抗ntb−a抗体ならびに関連する組成物および方法

Publications (3)

Publication Number Publication Date
JP2016503067A JP2016503067A (ja) 2016-02-01
JP2016503067A5 true JP2016503067A5 (OSRAM) 2017-01-12
JP6449777B2 JP6449777B2 (ja) 2019-01-09

Family

ID=50979291

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015549834A Expired - Fee Related JP6449777B2 (ja) 2012-12-21 2013-12-20 抗ntb−a抗体ならびに関連する組成物および方法
JP2018203019A Expired - Fee Related JP6817674B2 (ja) 2012-12-21 2018-10-29 抗ntb−a抗体ならびに関連する組成物および方法
JP2019238780A Withdrawn JP2020055870A (ja) 2012-12-21 2019-12-27 抗ntb−a抗体ならびに関連する組成物および方法
JP2022038055A Withdrawn JP2022066565A (ja) 2012-12-21 2022-03-11 抗ntb-a抗体ならびに関連する組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018203019A Expired - Fee Related JP6817674B2 (ja) 2012-12-21 2018-10-29 抗ntb−a抗体ならびに関連する組成物および方法
JP2019238780A Withdrawn JP2020055870A (ja) 2012-12-21 2019-12-27 抗ntb−a抗体ならびに関連する組成物および方法
JP2022038055A Withdrawn JP2022066565A (ja) 2012-12-21 2022-03-11 抗ntb-a抗体ならびに関連する組成物および方法

Country Status (10)

Country Link
US (4) US9708404B2 (OSRAM)
EP (1) EP2934585B1 (OSRAM)
JP (4) JP6449777B2 (OSRAM)
CN (2) CN107880126B (OSRAM)
AU (1) AU2013364043B2 (OSRAM)
CA (1) CA2893977C (OSRAM)
EA (1) EA031025B1 (OSRAM)
HK (1) HK1216850A1 (OSRAM)
IL (2) IL239211B (OSRAM)
WO (1) WO2014100740A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110372795A (zh) * 2007-08-02 2019-10-25 吉利德生物制剂公司 Lox和loxl2抑制剂及其应用
CN107880126B (zh) * 2012-12-21 2021-03-30 西雅图基因公司 抗ntb-a抗体及相关组合物和方法
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
AU2015315332A1 (en) * 2014-09-09 2017-03-30 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
CA2944085C (en) * 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
ES2881575T3 (es) * 2014-09-30 2021-11-29 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts / Univ Heidelberg Moléculas de unión, especialmente anticuerpos, que se unen a L1CAM (CD171)
WO2016070089A2 (en) * 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SG10202005460RA (en) 2015-06-30 2020-07-29 Seattle Genetics Inc Anti-ntb-a antibodies and related compositions and methods
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US12037410B2 (en) * 2018-02-13 2024-07-16 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
BR112021024997A2 (pt) 2019-07-03 2022-01-25 Oxford Biotherapeutics Ltd Anticorpos, polinucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica, métodos e uso
JP7671284B2 (ja) * 2019-10-04 2025-05-01 ティーエーイー ライフ サイエンシーズ Fc変異および部位特異的コンジュゲーション特性を含む抗体組成物
WO2021111005A1 (en) 2019-12-06 2021-06-10 Thoas Fioretos Novel agents and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
EP1252333A4 (en) 2000-01-25 2005-01-05 Nuvelo Inc METHODS AND SUBSTANCES RELATING TO CD84-TYPE POLYPEPTIDES AND POLYNUCLEOTIDES
AU2001253362A1 (en) 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
CA2421056A1 (en) 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
AU2002257088A1 (en) 2001-03-12 2002-09-24 Incyte Genomics, Inc. Immunoglobulin superfamily proteins
AU2002325333B2 (en) 2001-07-19 2008-04-03 Innate Pharma NTB-A, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
CA2476555A1 (en) 2002-02-14 2003-08-21 Nuvelo, Inc. Methods of therapy and diagnosis
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2003303305A1 (en) 2002-10-02 2004-09-30 Nuvelo,Inc. Novel nucleic acids and polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
JP5290756B2 (ja) * 2005-09-26 2013-09-18 メダレックス インコーポレイテッド 抗体−薬剤コンジュゲート及びその使用
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
CN101657306A (zh) * 2007-10-03 2010-02-24 赫尔曼斯·博阿达股份有限公司 手动陶瓷切割机
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2010022737A1 (en) 2008-08-29 2010-03-04 Symphogen A/S Anti-cd5 antibodies
CN102333859B (zh) * 2008-09-16 2015-04-22 三井化学株式会社 由来自植物的原料生产乳酸的方法及生产乳酸的细菌
EP2414393A1 (en) 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
PE20120622A1 (es) 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
EP2526115B1 (en) 2010-01-18 2018-08-01 Novo Nordisk Health Care AG Purification of blood coagulation factors
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
JP5965389B2 (ja) 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドProgenics Pharmaceuticals, Inc. クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
TR201802772T4 (tr) * 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
US9844593B2 (en) 2010-11-22 2017-12-19 Innate Pharma Sa Methods for treatment of recurrent hematological malignancies
BR112014000630A2 (pt) 2011-07-11 2017-02-14 Glenmark Pharmaceuticals Sa anticorpo antagonista ou fragmento do mesmo que se liga a uma ox40 humana, epítopo sobre o domínio extracelular ox40 humano, ácido nucleíco isolado, vetor, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição imunoconjugado, método para tratar um distúrbio mediado por ox40 em um indivíduo, uso de um anticorpo ou fragmento do mesmo, artigo de manufatura, kit e método para classificação in vitro
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN107880126B (zh) * 2012-12-21 2021-03-30 西雅图基因公司 抗ntb-a抗体及相关组合物和方法
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
SG10202005460RA (en) * 2015-06-30 2020-07-29 Seattle Genetics Inc Anti-ntb-a antibodies and related compositions and methods

Similar Documents

Publication Publication Date Title
JP2016503067A5 (OSRAM)
JP6526189B2 (ja) 抗pd−l1抗体並びにその治療及び診断のための使用
JP2016536020A5 (OSRAM)
HRP20240924T1 (hr) Anti - sirpalpha antitijela
JP2021501162A5 (OSRAM)
IL266756A (en) Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses
JP2016538318A5 (OSRAM)
JP2020513791A5 (OSRAM)
JP2018519263A5 (OSRAM)
JP2017534256A5 (OSRAM)
RU2017121327A (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
JP2016512551A5 (OSRAM)
JP2015520758A5 (OSRAM)
JP2011046732A5 (OSRAM)
RU2008149918A (ru) Антитела к nkg2a и их применения
JP2020504723A5 (OSRAM)
JP2015509947A5 (OSRAM)
PE20140848A1 (es) Anticuerpos monoclonales contra la proteina rgma y sus usos
JP2014533659A5 (OSRAM)
JP2016531915A5 (OSRAM)
JP2018513149A5 (OSRAM)
JP2017526370A5 (OSRAM)
JP2012070737A5 (OSRAM)
JP2015504306A5 (OSRAM)
JP2008540447A5 (OSRAM)